Answers are grounded in this paper and cite their sources.
Relapse risk is high after successful MAM/SAM treatment. Future research can consider optimization of anthropometric discharge criteria as a strategy to reduce postdischarge relapse risk, weighing the operational and financial tradeoffs associated with any modification. This trial was registered at PROSPERO as CRD42022342009.
No takes yet. Share an insight, caveat, or question.
Bliznashka et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: